GenMark Diagnostics Company Profile (NASDAQ:GNMK)

About GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics logoGenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GNMK
  • CUSIP: N/A
  • Web:
  • Market Cap: $440.62 million
  • Outstanding Shares: 54,667,000
Average Prices:
  • 50 Day Moving Avg: $9.46
  • 200 Day Moving Avg: $11.45
  • 52 Week Range: $8.00 - $13.67
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.68
  • P/E Growth: 0.15
Sales & Book Value:
  • Annual Revenue: $50.59 million
  • Price / Sales: 8.71
  • Book Value: $1.71 per share
  • Price / Book: 4.71
  • EBITDA: ($49,930,000.00)
  • Net Margins: -111.96%
  • Return on Equity: -109.89%
  • Return on Assets: -60.26%
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 3.60%
  • Quick Ratio: 3.39%
  • Average Volume: 424,153 shs.
  • Beta: 0.91
  • Short Ratio: 24.58

Frequently Asked Questions for GenMark Diagnostics (NASDAQ:GNMK)

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc. (NASDAQ:GNMK) issued its earnings results on Tuesday, August, 1st. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.05. The company earned $12.36 million during the quarter, compared to analysts' expectations of $12.44 million. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.30) earnings per share. View GenMark Diagnostics' Earnings History.

When will GenMark Diagnostics make its next earnings announcement?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for GenMark Diagnostics.

Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?

5 brokers have issued 12-month target prices for GenMark Diagnostics' stock. Their forecasts range from $13.00 to $17.00. On average, they expect GenMark Diagnostics' stock price to reach $14.40 in the next year. View Analyst Ratings for GenMark Diagnostics.

Who are some of GenMark Diagnostics' key competitors?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:

  • James Charles Fox Ph.D., Independent Chairman of the Board
  • Hany Massarany, President, Chief Executive Officer, Director
  • Scott Mendel, Chief Financial Officer
  • Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
  • Eric Stier, Senior Vice President, General Counsel, Secretary
  • Jennifer Anne Williams, Senior Vice President - Human Resources
  • Michael W Gleeson, Senior Vice President, North American Commercial Operations
  • Michael S Kagnoff, Director
  • Daryl Jay Faulkner, Independent Director
  • Lisa M. Giles, Independent Director

How do I buy GenMark Diagnostics stock?

Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GenMark Diagnostics stock can currently be purchased for approximately $8.06.

MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GenMark Diagnostics (NASDAQ:GNMK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.40 (78.66% upside)
Consensus Price Target History for GenMark Diagnostics (NASDAQ:GNMK)
Price Target History for GenMark Diagnostics (NASDAQ:GNMK)
Analysts' Ratings History for GenMark Diagnostics (NASDAQ:GNMK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/4/2017Needham & Company LLCReiterated RatingBuy$15.00MediumView Rating Details
9/27/2017Canaccord GenuityReiterated RatingBuyMediumView Rating Details
9/18/2017Bank of America CorporationInitiated CoverageBuy -> Buy$13.00HighView Rating Details
8/31/2017BTIG ResearchReiterated RatingBuy -> Buy$13.00HighView Rating Details
8/2/2017Cowen and CompanyReiterated RatingOutperform$17.00HighView Rating Details
7/29/2016J P Morgan Chase & CoBoost Price TargetOverweight$10.00 -> $13.00N/AView Rating Details
2/26/2016Raymond James Financial, Inc.Lower Price TargetOutperform$9.00 -> $7.25N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for GenMark Diagnostics (NASDAQ:GNMK)
Earnings by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Earnings History by Quarter for GenMark Diagnostics (NASDAQ GNMK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.26)N/AView Earnings Details
8/1/2017Q2 2017($0.32)($0.37)$12.44 million$12.36 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.28)($0.30)$12.55 million$12.54 millionViewListenView Earnings Details
2/28/2017Q416($0.27)($0.27)$15.03 million$14.90 millionViewListenView Earnings Details
11/3/2016Q316($0.31)($0.27)$10.36 million$10.80 millionViewN/AView Earnings Details
7/28/2016Q216($0.33)($0.30)$9.62 million$12.50 millionViewListenView Earnings Details
5/3/2016Q116($0.29)($0.30)$10.67 million$11.06 millionViewN/AView Earnings Details
2/23/2016Q415($0.27)($0.21)$12.34 million$13.20 millionViewListenView Earnings Details
10/27/2015Q315($0.31)($0.27)$8.24 million$8.80 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.29)$7.59 million$7.65 millionViewN/AView Earnings Details
5/5/2015Q115($0.24)($0.24)$10.10 million$10.10 millionViewN/AView Earnings Details
2/24/2015Q414($0.28)($0.21)$9.83 million$9.83 millionViewN/AView Earnings Details
10/30/2014Q314($0.32)($0.23)$5.80 million$6.30 millionViewN/AView Earnings Details
8/11/2014Q214($0.29)($0.27)$4.79 million$6.55 millionViewN/AView Earnings Details
5/6/2014Q114($0.25)($0.21)$6.40 million$7.91 millionViewN/AView Earnings Details
3/11/2014Q413($0.22)($0.21)$6.06 million$6.45 millionViewN/AView Earnings Details
11/12/2013Q313($0.27)($0.24)$4.60 million$4.64 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.26)($0.25)$5.05 million$5.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$9.53 million$11.10 millionViewN/AView Earnings Details
11/10/2011($0.32)($0.31)ViewN/AView Earnings Details
8/5/2011($0.45)($0.39)ViewN/AView Earnings Details
5/9/2011($0.49)($0.56)ViewN/AView Earnings Details
3/3/2011($0.52)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GenMark Diagnostics (NASDAQ:GNMK)
Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS


Dividend History for GenMark Diagnostics (NASDAQ:GNMK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GenMark Diagnostics (NASDAQ:GNMK)
Insider Ownership Percentage: 7.50%
Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Insider Trades by Quarter for GenMark Diagnostics (NASDAQ:GNMK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Eric StierSVPSell2,750$9.60$26,400.00View SEC Filing  
9/15/2017Jennifer Anne WilliamsSVPSell38,681$9.08$351,223.48View SEC Filing  
9/11/2017Michael KagnoffDirectorBuy2,500$9.15$22,875.00View SEC Filing  
9/5/2017Eric StierSVPSell311$9.75$3,032.25View SEC Filing  
8/21/2017Hany MassaranyInsiderSell8,311$9.45$78,538.95View SEC Filing  
8/21/2017Michael GleesonSVPSell1,933$9.45$18,266.85View SEC Filing  
8/21/2017Scott MendelCFOSell2,898$9.45$27,386.10View SEC Filing  
8/15/2017Scott MendelCFOSell1,752$10.16$17,800.32View SEC Filing  
8/2/2017Hany MassaranyInsiderSell1,629$10.33$16,827.57View SEC Filing  
8/2/2017Jon Faiz KayyemSVPSell138$10.33$1,425.54View SEC Filing  
8/2/2017Scott MendelCFOSell333$10.33$3,439.89View SEC Filing  
6/2/2017Michael GleesonSVPSell357$12.89$4,601.73View SEC Filing  
5/19/2017Hany MassaranyInsiderSell8,239$12.89$106,200.71View SEC Filing  
5/19/2017Michael GleesonSVPSell1,916$12.89$24,697.24View SEC Filing  
5/19/2017Scott MendelCFOSell2,135$12.89$27,520.15View SEC Filing  
5/16/2017Scott MendelCFOSell1,268$13.43$17,029.24View SEC Filing  
5/2/2017Eric StierSVPSell362$13.34$4,829.08View SEC Filing  
5/2/2017Hany MassaranyInsiderSell1,571$13.34$20,957.14View SEC Filing  
5/2/2017Scott MendelCFOSell232$13.34$3,094.88View SEC Filing  
3/3/2017Michael GleesonSVPSell353$12.29$4,338.37View SEC Filing  
2/21/2017Hany MassaranyInsiderSell33,537$10.08$338,052.96View SEC Filing  
2/21/2017Jon Faiz KayyemSVPSell5,250$10.08$52,920.00View SEC Filing  
2/21/2017Scott MendelCFOSell8,595$10.08$86,637.60View SEC Filing  
2/2/2017Hany MassaranyInsiderSell1,142$11.58$13,224.36View SEC Filing  
2/2/2017Jennifer Anne WilliamsSVPSell332$11.58$3,844.56View SEC Filing  
2/2/2017Scott MendelCFOSell235$11.58$2,721.30View SEC Filing  
1/19/2017Hany MassaranyInsiderSell27,124$12.47$338,236.28View SEC Filing  
1/19/2017Michael GleesonSVPSell9,569$12.47$119,325.43View SEC Filing  
1/19/2017Scott MendelCFOSell9,098$12.47$113,452.06View SEC Filing  
12/5/2016Jennifer Anne WilliamsSVPSell336$11.31$3,800.16View SEC Filing  
12/2/2016Michael GleesonSVPSell357$11.30$4,034.10View SEC Filing  
11/22/2016Michael KagnoffDirectorBuy2,000$11.80$23,600.00View SEC Filing  
11/14/2016Michael KagnoffDirectorBuy2,000$12.50$25,000.00View SEC Filing  
11/2/2016Hany MassaranyInsiderSell1,148$10.30$11,824.40View SEC Filing  
11/2/2016Michael GleesonSVPSell400$10.30$4,120.00View SEC Filing  
9/7/2016Hany MassaranyInsiderSell1,186$8.69$10,306.34View SEC Filing  
9/7/2016Jennifer Anne WilliamsSVPSell523$8.69$4,544.87View SEC Filing  
9/2/2016Jon Faiz KayyemSVPSell133$8.62$1,146.46View SEC Filing  
8/29/2016Jennifer Anne WilliamsSVPSell24,172$8.63$208,604.36View SEC Filing  
8/22/2016Michael GleesonSVPSell7,500$9.00$67,500.00View SEC Filing  
8/12/2016Lisa M GilesDirectorBuy823$9.40$7,736.20View SEC Filing  
8/2/2016Eric StierSVPSell367$9.88$3,625.96View SEC Filing  
8/2/2016Hany MassaranyInsiderSell1,147$9.88$11,332.36View SEC Filing  
6/7/2016Hany MassaranyCEOSell1,188$8.98$10,668.24View SEC Filing  
6/7/2016Michael GleesonSVPSell868$8.80$7,638.40View SEC Filing  
6/3/2016Ingo ChakravartySVPSell184$8.53$1,569.52View SEC Filing  
5/9/2016Ingo ChakravartySVPSell582$5.42$3,154.44View SEC Filing  
5/2/2016Eric StierSVPSell363$5.79$2,101.77View SEC Filing  
5/2/2016Hany MassaranyCEOSell1,160$5.79$6,716.40View SEC Filing  
3/10/2016Michael KagnoffDirectorBuy2,500$4.90$12,250.00View SEC Filing  
3/7/2016Hany MassaranyCEOSell1,193$5.76$6,871.68View SEC Filing  
3/7/2016Michael GleesonSVPSell559$5.76$3,219.84View SEC Filing  
3/2/2016Eric StierSVPSell365$4.87$1,777.55View SEC Filing  
2/9/2016Ingo ChakravartySVPSell697$5.04$3,512.88View SEC Filing  
2/3/2016Hany MassaranyCEOSell9,173$4.99$45,773.27View SEC Filing  
2/3/2016Michael GleesonSVPSell3,083$4.99$15,384.17View SEC Filing  
1/21/2016Hany MassaranyCEOSell648$6.80$4,406.40View SEC Filing  
1/21/2016Michael GleesonSVPSell227$6.80$1,543.60View SEC Filing  
12/8/2015Eric StierSVPSell240$7.26$1,742.40View SEC Filing  
12/8/2015Hany MassaranyCEOSell1,735$7.26$12,596.10View SEC Filing  
12/3/2015Hany MassaranyCEOSell3,571$7.71$27,532.41View SEC Filing  
12/3/2015Michael GleesonSVPSell1,664$7.62$12,679.68View SEC Filing  
11/3/2015Lisa M GilesDirectorBuy4,000$6.60$26,400.00View SEC Filing  
10/30/2015Michael KagnoffDirectorBuy5,000$6.70$33,500.00View SEC Filing  
10/30/2015Scott MendelCFOBuy10,000$6.47$64,700.00View SEC Filing  
10/29/2015Daryl FaulknerDirectorBuy4,000$7.33$29,320.00View SEC Filing  
9/15/2015Jennifer Anne WilliamsSVPSell14,245$9.98$142,165.10View SEC Filing  
9/14/2015Jennifer Anne WilliamsSVPSell9,245$10.00$92,450.00View SEC Filing  
9/11/2015Hany MassaranyCEOSell1,683$9.64$16,224.12View SEC Filing  
9/11/2015Jennifer Anne WilliamsSVPSell18,280$9.99$182,617.20View SEC Filing  
9/4/2015Jennifer Anne WilliamsSVPSell1,867$9.59$17,904.53View SEC Filing  
9/2/2015Hany MassaranyCEOSell3,865$9.62$37,181.30View SEC Filing  
8/24/2015Scott MendelCFOBuy10,000$9.10$91,000.00View SEC Filing  
6/16/2015Hany MassaranyCEOSell1,698$9.12$15,485.76View SEC Filing  
6/4/2015Michael GleesonSVPSell1,595$9.55$15,232.25View SEC Filing  
6/3/2015Hany MassaranyCEOSell3,486$9.47$33,012.42View SEC Filing  
4/9/2015Hany MassaranyCEOSell5,942$11.52$68,451.84View SEC Filing  
3/13/2015Jennifer Anne WilliamsSVPSell30,000$12.56$376,800.00View SEC Filing  
3/11/2015Hany MassaranyCEOSell28,110$11.88$333,946.80View SEC Filing  
3/11/2015Jeffrey Alan HawkinsSVPSell6,832$12.01$82,052.32View SEC Filing  
3/10/2015Jennifer Anne WilliamsSVPSell722$11.83$8,541.26View SEC Filing  
3/10/2015Michael KagnoffDirectorBuy5,000$11.84$59,200.00View SEC Filing  
3/9/2015Ingo ChakravartySVPSell3,310$12.06$39,918.60View SEC Filing  
1/22/2015Hany MassaranyCEOSell5,982$12.88$77,048.16View SEC Filing  
1/7/2015Hany MassaranyCEOSell4,858$13.00$63,154.00View SEC Filing  
12/16/2014Kevin C OboyleDirectorSell291$12.40$3,608.40View SEC Filing  
12/15/2014Eric StierSVPSell235$12.51$2,939.85View SEC Filing  
12/15/2014Hany MassaranyCEOSell1,700$12.51$21,267.00View SEC Filing  
12/4/2014Hany MassaranyCEOSell3,300$12.06$39,798.00View SEC Filing  
12/4/2014Jeffrey Alan HawkinsSVPSell1,350$12.06$16,281.00View SEC Filing  
10/31/2014Jon Faiz KayyemSVPSell6,000$11.01$66,060.00View SEC Filing  
10/8/2014Hany MassaranyCEOSell5,804$9.00$52,236.00View SEC Filing  
10/7/2014Michael GleesonSVPSell55$9.10$500.50View SEC Filing  
9/12/2014Hany MassaranyCEOSell1,678$9.86$16,545.08View SEC Filing  
9/5/2014Hany MassaranyCEOSell3,795$10.04$38,101.80View SEC Filing  
9/5/2014Michael GleesonSVPSell1,833$10.04$18,403.32View SEC Filing  
8/7/2014Michael GleesonSVPSell52$11.15$579.80View SEC Filing  
7/1/2014Jon Faiz KayyemSVPSell6,000$13.60$81,600.00View SEC Filing  
6/11/2014Hany MassaranyCEOSell1,115$11.64$12,978.60View SEC Filing  
6/5/2014Jon Faiz KayyemSVPSell1,483$10.69$15,853.27View SEC Filing  
6/3/2014Hany MassaranyCEOSell2,700$10.67$28,809.00View SEC Filing  
5/29/2014Kevin C OboyleDirectorSell1,603$10.98$17,600.94View SEC Filing  
5/28/2014Jon Faiz KayyemSVPSell6,000$11.06$66,360.00View SEC Filing  
5/8/2014Richard SlanskyCFOSell2,302$9.26$21,316.52View SEC Filing  
4/9/2014Hany MassaranyCEOSell3,985$9.87$39,331.95View SEC Filing  
3/26/2014Jennifer Anne WilliamsSVPSell30,195$9.97$301,044.15View SEC Filing  
3/5/2014Jon Faiz KayyemSVPSell7,355$12.46$91,643.30View SEC Filing  
1/16/2014Jon Faiz KayyemSVPSell50,000$14.05$702,500.00View SEC Filing  
1/7/2014Hany MassaranyCEOSell4,698$13.31$62,530.38View SEC Filing  
12/6/2013Michael GleesonSVPSell2,211$11.14$24,630.54View SEC Filing  
12/4/2013Hany MassaranyCEOSell3,968$11.14$44,203.52View SEC Filing  
10/9/2013Hany MassaranyCEOSell3,925$12.05$47,296.25View SEC Filing  
10/1/2013Jon Faiz KayyemSVPSell6,000$12.14$72,840.00View SEC Filing  
9/4/2013Jeffrey Alan HawkinsSVPSell1,890$11.60$21,924.00View SEC Filing  
9/3/2013Hany MassaranyCEOSell2,354$11.60$27,306.40View SEC Filing  
9/3/2013Jon Faiz KayyemSVPSell1,545$11.60$17,922.00View SEC Filing  
8/20/2013Jon Faiz KayyemSVPSell1,310$10.15$13,296.50View SEC Filing  
7/1/2013Jon Faiz KayyemSVPSell6,000$10.40$62,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GenMark Diagnostics (NASDAQ:GNMK)
Latest Headlines for GenMark Diagnostics (NASDAQ:GNMK)
DateHeadline logoRSI Alert: GenMark Diagnostics (GNMK) Now Oversold - October 18 at 12:53 AM logoETFs with exposure to GenMark Diagnostics, Inc. : October 16, 2017 - October 16 at 3:50 PM logoGenMark Diagnostics, Inc. (GNMK) Given Consensus Rating of "Buy" by Brokerages - October 15 at 9:28 AM logoIs GenMark Diagnostics Inc (GNMK) Undervalued? - October 12 at 8:03 PM logoCritical Comparison: GenMark Diagnostics (GNMK) versus Its Peers - October 12 at 12:28 AM logoAnalyzing GenMark Diagnostics (GNMK) and Its Rivals - October 9 at 8:28 PM logoGenMark Diagnostics' (GNMK) "Buy" Rating Reaffirmed at Needham & Company LLC - October 8 at 5:26 PM logoReviewing GenMark Diagnostics (GNMK) & Its Competitors - October 7 at 12:14 PM logoETFs with exposure to GenMark Diagnostics, Inc. : October 5, 2017 - October 5 at 7:26 PM logoGenMark Diagnostics, Inc. (GNMK) SVP Eric Stier Sells 2,750 Shares - October 4 at 9:08 PM logoGenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 - October 4 at 12:23 PM logoGenMark Diagnostics' (GNMK) Buy Rating Reiterated at Canaccord Genuity - October 1 at 5:14 PM logoToday's Research Report Coverage on Medical Equipment Stocks -- AcelRx Pharma, GenMark Diagnostics, ViewRay, and Nevro - September 25 at 10:33 AM logoGenMark Diagnostics, Inc. (GNMK) Receives Average Rating of "Buy" from Analysts - September 20 at 9:24 AM logoGenMark Diagnostics, Inc. (GNMK) Coverage Initiated at Bank of America Corporation - September 18 at 11:32 PM logoInsider Selling: GenMark Diagnostics, Inc. (GNMK) SVP Sells 38,681 Shares of Stock - September 15 at 10:46 PM logoGenMark Diagnostics, Inc. (GNMK) PT Lowered to $15.00 - September 13 at 8:04 AM logoComparing GenMark Diagnostics (GNMK) & Koninklijke Philips N.V. (PHG) - September 12 at 4:28 PM logoGenMark Diagnostics, Inc. (GNMK) Director Purchases $22,875.00 in Stock - September 11 at 10:20 PM logoGenMark Diagnostics, Inc. (GNMK) Earns Buy Rating from Analysts at BTIG Research - August 31 at 7:46 AM logoGenMark Diagnostics, Inc. (GNMK) Given Consensus Rating of "Hold" by Analysts - August 26 at 9:26 AM logo$14.61 Million in Sales Expected for GenMark Diagnostics, Inc. (GNMK) This Quarter - August 25 at 3:44 AM logoInsider Selling: GenMark Diagnostics, Inc. (GNMK) SVP Sells 1,933 Shares of Stock - August 23 at 4:44 PM logoGenMark Diagnostics, Inc. (GNMK) CFO Sells $27,386.10 in Stock - August 23 at 4:44 PM logoHany Massarany Sells 8,311 Shares of GenMark Diagnostics, Inc. (GNMK) Stock - August 23 at 4:20 PM logoGenMark Diagnostics, Inc. (GNMK) CFO Sells $17,800.32 in Stock - August 15 at 10:23 PM logoGenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : August 8, 2017 - August 8 at 6:51 PM logo Analysts Anticipate GenMark Diagnostics, Inc. (GNMK) Will Post Quarterly Sales of $14.81 Million - August 7 at 8:58 AM logoGenMark Diagnostics, Inc. (GNMK) Insider Sells $16,827.57 in Stock - August 4 at 4:30 PM logoGenMark Diagnostics, Inc. (GNMK) Forecasted to Earn FY2017 Earnings of ($1.12) Per Share - August 3 at 9:52 AM logoEdited Transcript of GNMK earnings conference call or presentation 1-Aug-17 12:30pm GMT - August 2 at 3:56 PM logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Stock Rating Reaffirmed by Cowen and Company - August 2 at 9:50 AM logoMid-Day Market Update: Pitney Bowes Drops On Earnings Miss; Lumber Liquidators Shares Climb - August 2 at 12:48 AM logoGenMark Reports Second Quarter 2017 Results - August 1 at 7:44 PM logoGenMark Diagnostics reports 2Q loss - August 1 at 7:44 PM logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - August 1 at 2:20 PM logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Receives Average Recommendation of "Buy" from Analysts - August 1 at 9:23 AM logoGenMark Diagnostics to Attend Canaccord Genuity’s 37th Annual Growth Conference - July 31 at 6:44 PM logoGenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : July 27, 2017 - July 27 at 7:44 PM logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Expected to Announce Quarterly Sales of $12.61 Million - July 16 at 8:58 AM logo Brokerages Expect GenMark Diagnostics, Inc. (GNMK) to Announce -$0.31 EPS - July 14 at 1:24 PM logoGenMark Diagnostics, Inc. (NASDAQ:GNMK) Given Average Rating of "Buy" by Brokerages - July 7 at 8:55 AM logoResearch Analysts Offer Predictions for GenMark Diagnostics, Inc.'s FY2018 Earnings (GNMK) - July 3 at 9:41 AM logoGenMark Diagnostics (GNMK) Announces CE Mark for ePlex Blood Culture Identification Gram-Positive and Gram-Negative Panels - June 29 at 11:08 PM logoGenMark Diagnostics (GNMK) Commences $65M Common Stock Offering - June 14 at 11:56 AM logoGenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel - April 21 at 5:27 PM logoCommit To Buy GenMark Diagnostics At $10, Earn 11.1% Annualized Using Options - April 7 at 10:04 AM logoGENMARK DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report - March 1 at 12:11 PM logoGENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition - March 1 at 12:11 PM logoGenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results - February 28 at 5:40 PM



GenMark Diagnostics (GNMK) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.